Anuual Report for the year 2025-26

Date: August 24, 2026 To, To, National Stock Exchange of India BSE Limited Limited 25th Floor, Exchange Plaza, C-1 Block G, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex Dalal Street, Fort, Bandra [E], Mumbai – 400051 Mumbai - 400 001 NSE Scrip Symbol: KRONOX BSE Scrip Code: 544187 Sub: Submission of Annual Report for the year ended March 31, 2026 along with Notice of 17th Annual General Meeting to be held on September 16, 2026. Ref: Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir /Madam, We wish to inform you that the 17th Annual General Meeting (AGM) of the KRONOX Lab Sciences Limited (Company) is scheduled to be held on Wednesday, September 16, 2026 at 11.00 AM through Video Conferencing/Other Audio Visual Means at the common venue at Block no. 353, Village: Ekalbara, Taluka: Padra, District: Vadodara 391440 to transact the business set-out in the Notice of the AGM dated August 12, 2026. Pursuant to Regulations 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we hereby submit the Annual Report of the Company for the Financial Year 2025-26 together with the Notice convening the 17th Annual General Meeting to be held on Wednesday, September 16, 2026. This is for your kind information and Records Thanking you For KRONOX Lab Sciences Limited Nikhil Goswami Company Secretary & Compliance O(cid:431)icer Membership No. A68272 ANNUAL REPORT 2025-26 SUCCESS THROUGH INNOVATION & QUALITY 01 Milestones 02 Our Clientele 03 CSR 04 Growing Numbers 05 Our Manufacturing Facilities & Capacity 06 Board Profile 07 Chairman Message 08 Corporate Information 89 - 99 100 - 106 107 - 138 ETAROPROC WEIVREVO 09 Notice of 17 th AGM 10 Board’s Report 11 Secretarial Audit Report 12 Certificate Of Compliance Of Corporate Governance 13 Certificate Of Non-Disqualification Of Directors 14 Management Discussion Analysis 12 Company Overview 13 Major Milestones Achieved 14 Manufacturing Infrastructure 15 Report on Corporate Governance 16 MD-CEO Certificate YROTUTATS STROPER 01-02 03-04 05-06 07-08 09-11 12-14 15-16 17-17 18-32 33-46 47-50 51-51 52-53 54-56 57-58 59-59 60-60 61-74 75-76 19 Independent Auditors Report 77-88 20 Financials Statements 89-96 21 Note of Accounts 97-116 SLAICNANIF Commencement of Manufacturing at Unit – I 9002 Commenced Exports of High Purity Specialty Fine Chemicals. Expansion of Unit – I for manufacturing of products for Pharma and Nutraceuticals. Acquisition of Land for Unit – II. Receipt of FSSC 22000 Certification. 4102 Incorporation of the Company. 8002 Milestone 01 Annual Report / 2025-26 5102 Commencement of Manufacturing at Unit – II (Leased). 9102 Acquisition of Land and Factory Shed of Unit – I & Unit – III into the Company. 2202 Acquisition of Land admeasuring to 20,471 sq.mtr. for Proposed Unit - IV. 3202 Listed of Company Stock on NSE & BSE 4202 Company Cross Turnover 100 cr. 62-5202 CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS Commencement of Manufacturing at Unit - II. Obtained FSSAI certification for manufacturing of food grade fine chemicals and ingredients. DDDDEEEEMMMMOOOONNNNSSSSTTTTRRRRAAAATTTTEEEEDDDD BBBBYYYY OOOOUUUURRRR GGGGRRRROOOOWWWWIIIINNNNGGGG NNNNUUUUMMMMBBBBEEEERRRRSSSS REVENUE GROWTH & PAT MARGIN (₹ IN LAKHS) FY23 FY24 FY25 FY26 EARNINGS PER SHARE CASH FLOW FROM (EPS) TREND OP ACT. (₹ IN LAKHS) 6.91 5.81 4.29 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 7.7559 2.6898 3.91001 9.12101 3500 10 3000 2500 2000 6 1500 1000 EBITDA MARGIN (₹ IN LAKHS) PAT MARGIN (₹ IN LAKHS) Revenue (₹ In Lakhs) PAT Margin % 10800 40 33% 33% 10400 31% 10000 27% 23% 9600 20 16% 9200 8800 8400 0 FY23 FY24 FY25 FY26 5.6691 5.1471 76.960,3 22.983,2 Growing Numbers 07 Annual Report / 2025-26 CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS EXPORT AS % ROCE % OF REVENUE ROE % 32 60 30 50 49% 28 40 38% 26% 32% 26 26% 30 24 20 24% 23% 22 10 20 0 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 WORKING CAPITAL INVENTORY DAYS RECEIVABLE DAYS EFFICIENCY (DAYS) PAYABLE DAYS 73 72 72 60 58 58 55 54 51 52 FY23 FY24 FY25 FY26 FINANCIAL SNAPSHOT METRICS FY26 FY25 FY24 FY23 Operating EBITDA Margin 33.86% 33.06% 31.51% 22.72% Operating EBIT Margin 31.83% 31.68% 30.08% 21.15% PAT Margin 25.99% 24.79% 23.35% 16.82% ROCE % 32.22% 38.03% 43.15% 49.46% ROE % 23.82% 28.26% 32.20% 36.65% Fixed Asset Turnover 3.52 3.60 3.40 6.01 Cash Convertion Cycle (No. of Days) 83 77 96 74 Net Worth / Shareholder Funds 11,612.71 9,010.50 6,630.50 4,475.08 Current Ratio 7.60 7.28 6.07 3.89 Liquidity Ratio (Quick Ratio / Acid Test Ratio) 6.80 6.55 4.87 2.84 Cash Flow from Opretaing Activity (₹ Lacs) 2,389.22 3,069.67 1,741.51 1,966.50 Cash Flow from Investing Activity (₹ Lacs) -2,382.02 -2,839.42 -1,731.22 -659.56 Cash Flow from Finance Activity (₹ Lacs) -36.20 -185.35 - -1,339.55 Exports as % of Revenue 32.39% 26.57% 24.75% 26.33% EPS - Basic / Diluted 7.51 6.91 5.81 4.30 Chairman Letter CCHHAAIIRRMMAANN LLEETTTTEERR TTOO SSHHAARREEHHOOLLDDEERRSS Dear Shareholders, including Excipients and has also maintained its revenue as ingredients, High Purity Reagents, compare to last year. Over the course of 1.7 decades, Pharmaceutical, nutraceutical and KRONOX Lab Sciences Ltd. Food Chemical. As per plan of development of Unit (KLSL) has emerged as a IV at Dahej, our Company has leading manufacturer of High KRONOX Lab Sciences operates a already obtained all the required Purity Speciality Fine chemicals facility that is certified FSSC 22000, permission for the Local and State catering to the needs of a cross GMP (Good Manufacturing departments like CETP, BEIL, GEB, section industry requirement. Practices), GLP (Good Laboratory Approval of Industrial Plan from Practices), and ISO 9001:2015, ISO GIDC etc. we have also obtained With all the support of the 14001:2015 and ISO 45001:2018. Environmental Clearance from stakeholders the Company was Additionally, where applicable, our Central Government. able to touched the turnover of products are certified KOSHER and 100 Crores in the year 2024-25 HALAL, ensuring compliance with Due to unforeseen circumstances and has continued in 2025-26. diverse cultural and religious the work at Unit IV, Dahej could not Let me acknowledge the work standards. These certifications be started. Now shortly the work will done by my fellow Directors and underscore our commitment to be started and the new deadlines the employees of the Company maintaining the highest levels of have been finalized by the and specially the Investors who quality, safety, and efficacy in our Company in which in coming two trusted us and have believed products. years the production will be use by investing. started at Dahej Unit and the KRONOX Lab Sciences Limited have whole Unit will be functional in We have built our product a capacity to manufacture to coming three years. portfolio through world class meet the demands of various technological adaptations industries and applications combined with a steady focus worldwide. Our manufacturing I extend an invitation to learn more on backward and forward facilities are located at Padra about KRONOX Lab Sciences Ltd. integration to emerge as a best taluka of Vadodara district with the browse our website. We welcome quality manufacturer. We also best-in-class global connectivity your comments at have long term relations with with different mode of transport info@kronoxlabsciences.com regards to supply commitments like Air, Water and Road. and/or with our customers both in India India has faced some difficult cs@kronoxlabsciences.com and abroad. times in last year due to tariff war from America and the war As we continuously growing in between Americal and Iran has our High Purity Speciality Fine made the year end more difficult. Your faithfully Chemicals Business with the But even after these difficult times Jogindersingh Jaswal portfolio of about 185 products India has survived. Your company Chairman & Managing Director 15 Annual Report / 2025-26 De [Showing first 8,000 characters — download PDF for full document]